<DOC>
	<DOCNO>NCT01264250</DOCNO>
	<brief_summary>In early phase study , healthy male volunteer randomly assign one dose either AZD2927 placebo . The objective ass Safety , Tolerability Pharmacokinetics AZD2927 .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Pharmacokinetics After Single Ascending Intravenous Doses AZD2927 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Provision sign date , write informed consent prior study specific procedure Healthy male subject age 18 45 year inclusive suitable vein cannulation repeat venepuncture Male subject willing use barrier contraception ie , condom , day dose 3 month dose Investigational Product ( IP ) Have body mass index ( BMI ) 19.0 30.0 kg/m2 weight least 50.0 kg 100.0 kg History clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study History presence gastrointestinal , mental , cardiac , hepatic renal disorder , condition know interfere absorption , distribution , metabolism excretion drug Abnormal vital sign , 10 minute supine rest Any clinically significant illness , medical/surgical procedure trauma within 4 week administration IP Any clinically significant abnormality clinical chemistry , haematology urinalysis result judge investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>drug metabolism</keyword>
</DOC>